Compare HubSpot Inc (HUBS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Johnson & Johnson — how do they compare? HubSpot Inc trades at $223.72 (market cap $11.84B), while Johnson & Johnson trades at $250.5 (market cap $598.96B). The key difference: Johnson & Johnson is far larger — about 50.6× HubSpot Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| HUBS | JNJ | |
|---|---|---|
Market Cap | $11.84B | $598.96B |
Sector | Technology | Health |
52-Week High | $560.90 | $267.24 |
52-Week Low | $170.39 | $164.36 |
Enterprise Value | $10.39B | $631.90B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.36, up 3.17% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with expanding profit margins. Recent earnings consistently beat expectations, and analyst sentiment remains overwhelmingly positive with 81% buy ratings. Technical indicators show the stock approaching resistance at $232 with RSI levels suggesting potential overbought conditions.
HUBS presents compelling growth prospects with accelerating AI integration and customer expansion, though elevated valuation metrics and competitive pressures warrant caution. The stock's 14% upside to consensus target of $264.06 reflects optimism about continued execution, but investors should monitor margin sustainability and market volatility risks in the software sector.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
